Pontryagin’s principle for state-constrained evolutionary differential complementarity system

This paper is devoted to the state-constrained optimal control problem of evolutionary variational inequality. In this paper, the control domain is not necessarily convex. Moreover, since our state constraint is quite general and, in many cases, it requires pointwise behavior of the state, the framework of the partial differential equation (instead of the abstract framework) is used. Some optimality conditions (in the form of Pontryagin’s principle) for optimal controls are established.     

Ambident electrophilicity of 4-nitrobenzochalcogenadiazoles: Kinetic studies and structure-reactivity relationships

The kinetics of the reactions of 4-nitrobenzofurazane 1a , 4-nitrobenzothiadiazole 1b , and 4-nitrobenzoselenadiazole 1c with a series of 4-Y-substituted phenoxide anions 2a-e (Y = OMe, Me, H, Cl, and CN) in aqueous solution at 20°C were investigated photometrically. The derived second-order rate constants (k₂) have been combined with the nucleophilicity parameters values of these series of anions 2a-e to determine the electrophilicity parameters E of electrophiles 1a-c according to the linear free-energy relationship (log k₂)/s versus N. General reactivity of these electrophiles 1a-c is found to be fairly similar with E values ranging in −10.77 ± 0.61 < E < −7.53 ± 0.29. The comparison with structurally related neutral electron-deficient heteroaromatic and aromatic compounds revealed that 1a - c are more reactive than 1,3,5-trinitrobenzene, as benchmark aromatic electrophile used in nucleophilic addition or substitution processes. The rate constants for the reactions of 4-nitrobenzochalcogenadiazoles 1a-c with some other nucleophiles were measured and found to agree with those calculated from Mayr's equation. Finally, analysis of the rate data in terms of the Brønsted approach reveals that 1a-c exhibits especially low intrinsic reactivity in σ-adducts 3 forming reactions.     

Synthesis and structures of substituted triphenyl(phenylimino)phosphoranes

Three substituted triphenyl(phenylimino)phosphoranes, namely (4‐cyanophenylimino)triphenylphosphorane, C₂₅H₁₉N₂P, (I), (4‐nitrophenylimino)triphenylphosphorane, C₂₄H₁₉N₂O₂P, (II), and (3‐nitrophenylimino)triphenylphosphorane, C₂₄H₁₉N₂O₂P, (III), were synthesized as precursors for the preparation of substituted diphenylcarbodiimides. All three compounds display a supramolecular arrangement in which the substituted benzene rings are organized in an antiparallel fashion. The nitro group on the ring participates in C—H...O and O...π interactions, forming intermolecular dimers. Compound (III) shows disorder which involves the rotation of one of the phenyl rings of the triphenylphosphine group.     

Synthesis,structural and chemosensitivity studies of arene d6 metal complexes having N‐phenyl‐N´‐(pyridyl/pyrimidyl)thiourea derivatives

The d⁶ metal complexes of thiourea derivatives were synthesized to investigate its cytotoxicity. Treatment of various N‐phenyl‐N´ pyridyl/pyrimidyl thiourea ligands with half‐sandwich d⁶ metal precursors yielded a series of cationic complexes. Reactions of ligand (L1‐L3) with [(p‐cymene)RuCl₂]₂ and [Cp*MCl₂]₂ (M = Rh/Ir) led to the formation of a series of cationic complexes bearing general formula [(arene)M(L1)к²_(N,S)Cl]⁺, [(arene)M(L2)к²_(N,S)Cl]⁺ and [(arene)M(L3)к²_(N,S)Cl]⁺ [arene = p‐cymene, M = Ru ( 1 , 4 , 7 ); Cp*, M = Rh ( 2 , 5 , 8 ); Cp*, Ir ( 3 , 6 , 9 )]. These compounds were isolated as their chloride salts. X‐ray crystallographic studies of the complexes revealed the coordination of the ligands to the metal in a bidentate chelating N,S‐ manner. Further the cytotoxicity studies of the thiourea derivatives and its complexes evaluated against HCT‐116 (human colorectal cancer), MIA‐PaCa‐2 (human pancreatic cancer) and ARPE‐19 (non‐cancer retinal epithelium) cancer cell lines showed that the thiourea ligands displayed no activity. Upon complexation however, the metal compounds possesses cytotoxicity and whilst potency is less than cisplatin, several complexes exhibited greater selectivity for HCT‐116 or MIA‐PaCa‐2 cells compared to ARPE‐19 cells than cisplatin in vitro. Rhodium complexes of thiourea derivatives were found to be more potent as compared to ruthenium and iridium complexes.     

Cyclophosphazenes and Relatives as Anticancer Drugs

Abstract

Aziridinocyclophosphazenes N₃P₃Az₆ (code name MYKO 63), N₄P₄Az₈ (code name MYKO 83) and relatives constituted the first generation of anticancer drugs whose efficiency on several rodent neoplasms was made conspicuous in a quantitative manner from 1976 to 1978 both in our Laboratory and by EORTC Screening Pharmacology Groups¹. MYKO 63 appeared at that time as a promising drug for industrial development owing to its wide spectrum of activity and its very low mutagenicity². However, this hope failed as a consequence of a cumulative toxicity which occurs upon heavy polyinjections schedules. In other words, MYKO 63 exhibits an uncomfortable kinetics of action on the tumor - and, consequently, of excretion - presumably due (it was our assumption) to a too high chemical stability of the molecule.